Innovent Biologics (STU:6IB) Moat Score: 6/10 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6IB Innovent Biologics Inc STU:6IB
80 GF Score
Price €10.10
GF Value €11.08
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics Moat Score?

Innovent Biologics STU:6IB +4.21% 80 Moat Score is 6 as of Jul. 21, 2026. GuruFocus rates STU:6IB with a GF Score™ of 80/100 and a GF Value™ of €11.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, Innovent Biologics ranks better than 98.93% on this metric.

Innovent Biologics has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Innovent Biologics has Narrow Moat: Innovent Biologics Inc has a strong narrow moat due to its robust pipeline of biologics and strategic partnerships. It benefits from valuable intellectual property and significant regulatory barriers, but lacks the brand strength and pricing power for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Innovent Biologics might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Innovent Biologics  (STU:6IB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Innovent Biologics Moat Score Related Terms

STU:6IB vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Innovent Biologics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Moat Score distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Moat Score falls into.


STU:6IB
80GF Score
Innovent Biologics Inc STU:6IB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Innovent Biologics (STU:6IB) has a Moat Score of 6 as of Jul. 21, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Innovent Biologics ranks #15 out of 1396 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Innovent Biologics' Moat Score too high?
Innovent Biologics' current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Innovent Biologics' value of 6 is 200% above this industry median. Based on the distribution chart, Innovent Biologics ranks #15 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #15 out of 1396 companies for Moat Score. This places Innovent Biologics in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Innovent Biologics' value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Fairly Valued. The stock's GF Value™ is €11.08, compared to a current price of €10.10 — trading 8.8% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current Moat Score is 6 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innovent Biologics (STU:6IB) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of €10.10 is trading 8.8% below its estimated GF Value™ of €11.08. GuruFocus considers Innovent Biologics to be Fairly Valued.

Key valuation signals for STU:6IB:

  • Moat Score: 6
  • GF Value™: €11.08 vs. price of €10.10 (8.8% below fair value)
  • GF Score™: 80/100 with 2 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1396)

No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score

Get the complete analysis for STU:6IB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.10
Price
€11.08
GF Value